-
Boehringer Ingelheim Partners with ExpressionEdits on Gene Therapy Tech
•
German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based ExpressionEdits. The deal leverages ExpressionEdits’ Genetic Syntax Engine technology to advance gene therapy development. Technology DetailsThe Genetic Syntax Engine is a proprietary AI-powered platform. It uses optimized introns to enhance gene expression without altering the…
